Mobile Technology and Motivational Interviewing in Type 2 Diabetes Patients

Inonu University

Status: Completed

Conditions: Mobile Technology; Gaming; Quality of Life; Type 2 Diabetes Mellitus; Motivational Interviewing; Self-Management

Treatments: Behavioral: Patient Education with Game-Based Mobile Technology and Motivational Interviewing

Study type: Interventional

Funder types: Other

Identifiers

NCT05919706

Diabetes Mellitus and Mobile

Details and patient eligibility

About

Type 2 diabetes patients were divided into experimental and control groups. Patients in the control group received regular nursing care, while those in the experimental group received MI, which is empowered by game-based mobile technology. Pre-test, post-test and follow-up test self-management, quality of life and satisfaction levels scores were determined.

Full description

A randomized controlled and experimental study design was used to conduct this research on 64 patients with Type 2 DM. Purpose of this study was to explore how motivational interviewing powered by game-based mobile technology affected self-management, quality of life, and satisfaction in Type 2 diabetes patients.

Enrollment: 64 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Being 18 years or older,
• Having a diagnosis of Type 2 Diabetes Mellitus according to the ADA diagnostic criteria,
• Being on oral antidiabetic and/or insulin therapy,
• Having a smart phone and knowing how to use it,
• Internet connection (to install mobile technology application),
• Not having participated in motivational interviewing (MG) training before,
• Not having vision and hearing problems,
• Not having a communication problem,
• To be able to read, write and speak Turkish,
• Volunteering to participate in the study and continue the study process.

Exclusion criteria

• Having a diagnosis of Type 1 and/or Gestational Diabetes Mellitus,
• Having serious health problems that prevent participation in motivational interviewing,
• Using steroid therapy,
• Having complications that may develop in the long term due to diabetes and having advanced retinopathy, neuropathy, amputation history or active foot wound,
• Having mental confusion, having any psychiatric problems and/or using a psychiatric drug,
• Being unwilling to participate in the study and/or not wanting to continue the study process.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

64 participants in 2 patient groups

Experimental Group

Experimental group

Description:

Pre-test data were collected from patients with Patient Information and Follow-up Form, Diabetes Self-Management Scale (DSMQ) and Short Form-36 Quality of Life Scale (SF-36). After the pre-test, a educational program and a game-based mobile technology application were carried out for 4 weeks, 2 days a week at intervals. After the educational program were completed, motivational interviews were conducted once a week for 4 weeks. In this process, it was ensured that the game-based mobile technology application continued. Post-test data were collected with DSMQ and SF-36 at 2 months (8 weeks after the pre-test). After the post-test, the patients were followed up for 4 weeks. After the follow, with the Patient Information and Follow-up Form, DSMQ, SF-36, and the Satisfaction Questionnaire the follow-test data was collected.

Treatment:

Behavioral: Patient Education with Game-Based Mobile Technology and Motivational Interviewing

Control Group

No Intervention group

Description:

Pre-test data were collected from patients with Patient Information and Follow-up Form, Diabetes Self-Management Scale DSMQ) and Short Form-36 Quality of Life Scale (SF-36). After the pre-test data were collected, no intervention was applied to the patients for 3 months (12 weeks), except for routine nursing care. Posttest data were collected with DSMQ and SF-36 2 months (8 weeks) after the pretest data. After the last test, the patients were followed up for 4 weeks, and 3 months (12 weeks) after the start of the study, the Patient Information and Follow-up Form (only the parts containing the features related to the disease and metabolic control variables), DSMQ and SF-36 Scale and follow-up test data were collected.